Efficacy of infliximab in a patient with refractory idiopathic retroperitoneal fibrosis

M. G. Catanoso, L. Spaggiari, L. Magnani, N. Pipitone, A. Versari, L. Boiardi, G. Pazzola, P. Pattacini, C. Salvarani

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Glucocorticoids are the mainstay of treatment of idiopathic retroperitoneal fibrosis (IRF). However, relapses are frequent upon tapering of the glucocorticoid dose. A variety of traditional immunosuppressants have been proposed as steroid-sparing agents, but some patients fail to adequately respond to combined glucocorticoid and immunosuppressive therapy. We report a patient with IRF refractory to combined glucocorticoid and methotrexate therapy treated with the anti-TNF-α monoclonal antibody infliximab. Infliximab was administered at 5 mglkglbodyweight at week 0,2, 6 and 8-weekly thereafter for 3 consecutive years. Drug efficacy and safety were assessed clinically and by laboratory tests at treatment onset and subsequently before each infusion. In addition, 18F-Fluorodeoxyglucose (FDG) positron emission computerised tomography (PET/CT) and abdominal CT scans were used to monitor disease activity and response to treatment. Infliximab therapy resulted in a satisfactory clinical and laboratory response paralleled by an improvement in imaging findings. No serious adverse events were noted. Infliximab may be an effective and safe treatment for refractory IRF. A controlled study is required to confirm our findings.

Original languageEnglish
Pages (from-to)776-778
Number of pages3
JournalClinical and Experimental Rheumatology
Volume30
Issue number5
Publication statusPublished - 2012

Fingerprint

Retroperitoneal Fibrosis
Glucocorticoids
Immunosuppressive Agents
Therapeutics
Fluorodeoxyglucose F18
Proxy
Infliximab
Methotrexate
Positron-Emission Tomography
Steroids
Monoclonal Antibodies
Safety
Recurrence

Keywords

  • Idiopathic retroperitoneal fibrosis
  • Infliximab

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Efficacy of infliximab in a patient with refractory idiopathic retroperitoneal fibrosis. / Catanoso, M. G.; Spaggiari, L.; Magnani, L.; Pipitone, N.; Versari, A.; Boiardi, L.; Pazzola, G.; Pattacini, P.; Salvarani, C.

In: Clinical and Experimental Rheumatology, Vol. 30, No. 5, 2012, p. 776-778.

Research output: Contribution to journalArticle

Catanoso, MG, Spaggiari, L, Magnani, L, Pipitone, N, Versari, A, Boiardi, L, Pazzola, G, Pattacini, P & Salvarani, C 2012, 'Efficacy of infliximab in a patient with refractory idiopathic retroperitoneal fibrosis', Clinical and Experimental Rheumatology, vol. 30, no. 5, pp. 776-778.
Catanoso, M. G. ; Spaggiari, L. ; Magnani, L. ; Pipitone, N. ; Versari, A. ; Boiardi, L. ; Pazzola, G. ; Pattacini, P. ; Salvarani, C. / Efficacy of infliximab in a patient with refractory idiopathic retroperitoneal fibrosis. In: Clinical and Experimental Rheumatology. 2012 ; Vol. 30, No. 5. pp. 776-778.
@article{663c1a725df34f10bba89d46816f59e1,
title = "Efficacy of infliximab in a patient with refractory idiopathic retroperitoneal fibrosis",
abstract = "Glucocorticoids are the mainstay of treatment of idiopathic retroperitoneal fibrosis (IRF). However, relapses are frequent upon tapering of the glucocorticoid dose. A variety of traditional immunosuppressants have been proposed as steroid-sparing agents, but some patients fail to adequately respond to combined glucocorticoid and immunosuppressive therapy. We report a patient with IRF refractory to combined glucocorticoid and methotrexate therapy treated with the anti-TNF-α monoclonal antibody infliximab. Infliximab was administered at 5 mglkglbodyweight at week 0,2, 6 and 8-weekly thereafter for 3 consecutive years. Drug efficacy and safety were assessed clinically and by laboratory tests at treatment onset and subsequently before each infusion. In addition, 18F-Fluorodeoxyglucose (FDG) positron emission computerised tomography (PET/CT) and abdominal CT scans were used to monitor disease activity and response to treatment. Infliximab therapy resulted in a satisfactory clinical and laboratory response paralleled by an improvement in imaging findings. No serious adverse events were noted. Infliximab may be an effective and safe treatment for refractory IRF. A controlled study is required to confirm our findings.",
keywords = "Idiopathic retroperitoneal fibrosis, Infliximab",
author = "Catanoso, {M. G.} and L. Spaggiari and L. Magnani and N. Pipitone and A. Versari and L. Boiardi and G. Pazzola and P. Pattacini and C. Salvarani",
year = "2012",
language = "English",
volume = "30",
pages = "776--778",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "5",

}

TY - JOUR

T1 - Efficacy of infliximab in a patient with refractory idiopathic retroperitoneal fibrosis

AU - Catanoso, M. G.

AU - Spaggiari, L.

AU - Magnani, L.

AU - Pipitone, N.

AU - Versari, A.

AU - Boiardi, L.

AU - Pazzola, G.

AU - Pattacini, P.

AU - Salvarani, C.

PY - 2012

Y1 - 2012

N2 - Glucocorticoids are the mainstay of treatment of idiopathic retroperitoneal fibrosis (IRF). However, relapses are frequent upon tapering of the glucocorticoid dose. A variety of traditional immunosuppressants have been proposed as steroid-sparing agents, but some patients fail to adequately respond to combined glucocorticoid and immunosuppressive therapy. We report a patient with IRF refractory to combined glucocorticoid and methotrexate therapy treated with the anti-TNF-α monoclonal antibody infliximab. Infliximab was administered at 5 mglkglbodyweight at week 0,2, 6 and 8-weekly thereafter for 3 consecutive years. Drug efficacy and safety were assessed clinically and by laboratory tests at treatment onset and subsequently before each infusion. In addition, 18F-Fluorodeoxyglucose (FDG) positron emission computerised tomography (PET/CT) and abdominal CT scans were used to monitor disease activity and response to treatment. Infliximab therapy resulted in a satisfactory clinical and laboratory response paralleled by an improvement in imaging findings. No serious adverse events were noted. Infliximab may be an effective and safe treatment for refractory IRF. A controlled study is required to confirm our findings.

AB - Glucocorticoids are the mainstay of treatment of idiopathic retroperitoneal fibrosis (IRF). However, relapses are frequent upon tapering of the glucocorticoid dose. A variety of traditional immunosuppressants have been proposed as steroid-sparing agents, but some patients fail to adequately respond to combined glucocorticoid and immunosuppressive therapy. We report a patient with IRF refractory to combined glucocorticoid and methotrexate therapy treated with the anti-TNF-α monoclonal antibody infliximab. Infliximab was administered at 5 mglkglbodyweight at week 0,2, 6 and 8-weekly thereafter for 3 consecutive years. Drug efficacy and safety were assessed clinically and by laboratory tests at treatment onset and subsequently before each infusion. In addition, 18F-Fluorodeoxyglucose (FDG) positron emission computerised tomography (PET/CT) and abdominal CT scans were used to monitor disease activity and response to treatment. Infliximab therapy resulted in a satisfactory clinical and laboratory response paralleled by an improvement in imaging findings. No serious adverse events were noted. Infliximab may be an effective and safe treatment for refractory IRF. A controlled study is required to confirm our findings.

KW - Idiopathic retroperitoneal fibrosis

KW - Infliximab

UR - http://www.scopus.com/inward/record.url?scp=84870261334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870261334&partnerID=8YFLogxK

M3 - Article

VL - 30

SP - 776

EP - 778

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 5

ER -